WO2009064509A1 - Implant annulaire - Google Patents
Implant annulaire Download PDFInfo
- Publication number
- WO2009064509A1 WO2009064509A1 PCT/US2008/053300 US2008053300W WO2009064509A1 WO 2009064509 A1 WO2009064509 A1 WO 2009064509A1 US 2008053300 W US2008053300 W US 2008053300W WO 2009064509 A1 WO2009064509 A1 WO 2009064509A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue
- implant according
- anchoring element
- annular anchoring
- substitute
- Prior art date
Links
- 239000007943 implant Substances 0.000 title claims abstract description 58
- 210000001519 tissue Anatomy 0.000 claims abstract description 106
- 238000004873 anchoring Methods 0.000 claims abstract description 56
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 22
- 238000002513 implantation Methods 0.000 claims abstract description 14
- 238000009434 installation Methods 0.000 claims abstract description 3
- 210000000845 cartilage Anatomy 0.000 claims description 38
- 210000005065 subchondral bone plate Anatomy 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 230000008439 repair process Effects 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 19
- -1 analgesic Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 210000001612 chondrocyte Anatomy 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 239000003102 growth factor Substances 0.000 claims description 10
- 229920005615 natural polymer Polymers 0.000 claims description 9
- 229920001059 synthetic polymer Polymers 0.000 claims description 9
- 230000002188 osteogenic effect Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 210000003041 ligament Anatomy 0.000 claims description 6
- 229920001610 polycaprolactone Polymers 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 210000000963 osteoblast Anatomy 0.000 claims description 5
- 229910010293 ceramic material Inorganic materials 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 230000005499 meniscus Effects 0.000 claims description 4
- 230000000278 osteoconductive effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 210000002435 tendon Anatomy 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 230000002648 chondrogenic effect Effects 0.000 claims description 3
- 210000002889 endothelial cell Anatomy 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 230000002138 osteoinductive effect Effects 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- 208000006735 Periostitis Diseases 0.000 claims description 2
- 210000001789 adipocyte Anatomy 0.000 claims description 2
- 210000002798 bone marrow cell Anatomy 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000001074 muscle attachment cell Anatomy 0.000 claims description 2
- 210000003098 myoblast Anatomy 0.000 claims description 2
- 210000002997 osteoclast Anatomy 0.000 claims description 2
- 210000004409 osteocyte Anatomy 0.000 claims description 2
- 210000003460 periosteum Anatomy 0.000 claims description 2
- 210000004180 plasmocyte Anatomy 0.000 claims description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 2
- 210000002536 stromal cell Anatomy 0.000 claims description 2
- 210000001258 synovial membrane Anatomy 0.000 claims description 2
- 210000003954 umbilical cord Anatomy 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 description 25
- 230000007547 defect Effects 0.000 description 22
- 210000001188 articular cartilage Anatomy 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 230000035876 healing Effects 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 210000000968 fibrocartilage Anatomy 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- 201000009859 Osteochondrosis Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000003035 hyaline cartilage Anatomy 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000004623 platelet-rich plasma Anatomy 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 229920001308 poly(aminoacid) Polymers 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000013201 Stress fracture Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000008468 bone growth Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001804 debridement Methods 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- ADFVYWCDAKWKPH-UHFFFAOYSA-N 4-ethoxycarbonylbenzoic acid Chemical compound CCOC(=O)C1=CC=C(C(O)=O)C=C1 ADFVYWCDAKWKPH-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 2
- 108010066486 EGF Family of Proteins Proteins 0.000 description 2
- 102000018386 EGF Family of Proteins Human genes 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 229920002201 Oxidized cellulose Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920003232 aliphatic polyester Polymers 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000001175 calcium sulphate Substances 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000010952 cobalt-chrome Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000004276 hyalin Anatomy 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000013150 knee replacement Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000003891 oxalate salts Chemical class 0.000 description 2
- 229940107304 oxidized cellulose Drugs 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001299 polypropylene fumarate Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010061762 Chondropathy Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000002804 Osteochondritis Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000012936 correction and preventive action Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 238000012829 orthopaedic surgery Methods 0.000 description 1
- 208000007656 osteochondritis dissecans Diseases 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229920000431 shape-memory polymer Polymers 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003932 viscosupplement Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30721—Accessories
- A61F2/30749—Fixation appliances for connecting prostheses to the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/30004—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
- A61F2002/30032—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in absorbability or resorbability, i.e. in absorption or resorption time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/30199—Three-dimensional shapes
- A61F2002/302—Three-dimensional shapes toroidal, e.g. rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/30199—Three-dimensional shapes
- A61F2002/30224—Three-dimensional shapes cylindrical
- A61F2002/30235—Three-dimensional shapes cylindrical tubular, e.g. sleeves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30316—The prosthesis having different structural features at different locations within the same prosthesis; Connections between prosthetic parts; Special structural features of bone or joint prostheses not otherwise provided for
- A61F2002/30535—Special structural features of bone or joint prostheses not otherwise provided for
- A61F2002/30579—Special structural features of bone or joint prostheses not otherwise provided for with mechanically expandable devices, e.g. fixation devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30667—Features concerning an interaction with the environment or a particular use of the prosthesis
- A61F2002/30677—Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30721—Accessories
- A61F2/30749—Fixation appliances for connecting prostheses to the body
- A61F2002/30751—Fixation appliances for connecting prostheses to the body for attaching cartilage scaffolds to underlying bone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
- A61F2002/30766—Scaffolds for cartilage ingrowth and regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2002/3092—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth having an open-celled or open-pored structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0065—Three-dimensional shapes toroidal, e.g. ring-shaped, doughnut-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0069—Three-dimensional shapes cylindrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/003—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
Definitions
- This invention relates generally to the field of orthopaedic surgery for the repair and replacement of damaged cartilage.
- damaged tissue may be other types of tissue, for example, bone or skin, including damaged surfaces of or defects in the bone itself.
- Articular cartilage is a highly organized avascular tissue composed of chondrocytes embedded within an extracellular matrix of collagens, proteoglycans and non-collagenous proteins. Its primary function is to enable the smooth articulation of joint surfaces, and to cushion compressive, tensile, and shearing forces.
- Hyaline cartilage has one of the lowest coefficients of friction known for any surface to surface contact.
- Cartilage is frequently injured, often as a result of sports related trauma, but due to its avascular nature, articular cartilage has very limited capacity for repair. It is well known that the capacity of articular cartilage for repair is limited. Partial-thickness defects in the articular cartilage do not heal spontaneously.
- Injuries of the articular cartilage that do not penetrate the subchondral bone do not heal and usually progress to the degeneration of the articular surface. Injuries that penetrate the subchondral bone, and hence the vasculature, undergo repair through the formation of fibrocartilage. Although fibrocartilage fills and covers the defect, this is considered sub-optimal tissue from the biomechanical standpoint.
- the fibrocartilage is made to resist tension forces, while the hyaline cartilage is made to resist compression forces, to enable smooth articulation, and to withstand long-term variable cyclic load and shearing forces.
- the principal goals for surgical management of the symptomatic chondral and osteochondral defects are to reduce symptoms, improve joint congruence by restoring the joint surface with the best possible tissue, and to prevent additional cartilage deterioration.
- debridement and lavage which is typically reserved for lower demand older patients with small lesions ( ⁇ 2 to 3 cm 2 ) and limited symptoms who would have difficulty with activity or weight-bearing restrictions post-operatively. It entails arthroscopic surgery where two to three small incisions are placed about the knee to place a small camera and instruments inside the joint to evaluate and treat the lesions. Loose chondral flaps that can cause mechanical symptoms are removed. Relief from this type of procedure may be incomplete or temporary because no attempt has been made to restore or repair the cartilage lesion. The recovery time from this type of procedure is relatively short, with immediate full weight-bearing and unrestricted activities.
- Abrasion chondroplasty utilizes a high-speed endoscopic burr to resect a damaged area of cartilage to bleeding subchondral bone. This allows a blood clot to form over the defect which develops into a repair tissue of fibrocartilage that is relatively thin and tends to deteriorate overtime.
- microfracture may be performed in an attempt to stimulate new cartilage growth.
- the treatment involves a disruption of subchondral bone in an attempt to induce bleeding and to initiate primitive stem cell migration from the bone marrow into the cartilage defect site.
- primitive stem cells which are capable of differentiating into bone and cartilage under the influence of various biologic and mechanical intra-articular factors.
- the subchondral bone is penetrated in order to reach a zone of vascularisation, stimulating the formation of a fibrin clot containing pluripotential stem cells. This clot differentiates and remodels, resulting in a fibrocartilaginous repair tissue.
- fibrocartilage Although fibrocartilage often appears to offer the patient significant pain relief, this tissue lacks several key structural components to perform the mechanical functions, as a wear-resistant and as a weight-bearing surface.
- the fibrocartilage repair tissue does not produce a proper compressive stiffness against applied mechanical load and thus is subjected to an excessive deformation under physiological loading. This in turn causes a mechanical failure of the repaired tissue and eventually leads to a recurrence of degeneration of the repaired cartilage. Results for this technique are similar to abrasion chondroplasty.
- Ostetoplasty is another surgical technique that can potentially restore the height and the shape of articulating surface in focal osteochondral defects, with composite autologous material that contains all necessary ingredients: hyaline articular cartilage, intact tidemark, and a firm bone carrier.
- These osteochondral autograft plugs are most commonly transplanted to symptomatic lesions involving the femoral condyles.
- the lesions should be small to medium-sized (0.5 to 3 cm 2 ) because the amount of donor tissue available is limited.
- the main problem with this reconstructive technique is the limited availability of autografts, which significantly reduces the choice of treatable defects down to a small focal chondral defect, and a long term donor morbidity in multiple donor sites.
- Deep and large, crater-like osteochondral defects are not suitable for osteochondral autograft transplantation, mainly because of the limited availability of autologous osteochondral grafts.
- the procedure is also technically difficult, as all grafts must be taken with the axis of the harvesting coring drill being kept perpendicular to the reticular surface at the point of harvest.
- it is difficult to reconstruct the subchondral bone and restore the contour of the defect area, and to cover the entire defect area with hyaline articular cartilage.
- the dead spaces between circular grafts, the lack of integration of donor and recipient hyaline cartilage, different orientation, thickness and mechanical properties of donor and recipient hyaline cartilage are further sources of clinical concern.
- Autologous Chondrocyte Implantation is another advanced therapy which is used for intermediate to high-demand patients who have failed arthroscopic debridement or microfracture.
- the technique is used for larger (2 to 10 cm 2 ) symptomatic lesions involving both the femoral condyles and trochlear and the patella. It allows chondrocytes to be harvested from the patients knee and cultured and multiplied. The fresh chondrocytes are then re- implanted into the patients knee and cause hyaline-like cartilage to repair the defect in articulating surface.
- the ACI restores the articular surface with the patients own hyaline-like cartilage without compromising the integrity of healthy tissue or the subchondral bone.
- TJR total joint replacements
- Prosthetics available for the knee joint include either total knee replacements (TKR), whereby the entire knee joint is replaced or unicompartmental knee replacements (UKR) where a single compartment of the knee joint, typically the medial condyle, is replaced.
- TKR total knee replacements
- UBR unicompartmental knee replacements
- the latter treatment is a common eventuality for the patient with a large focal defect.
- These patients are managed with anti-inflammatory drugs, however, the remaining articular cartilage eventually erodes away resulting in pain, and loss of mobility.
- total joint replacement the patient may face future problems associated with loosening of the implant, which may occur as a result of either wear, breakdown of the cement, osteolysis, or infection. Furthermore, healthy bone tissue has to be removed to accommodate the implant.
- Total joint replacement is regarded as a last resort treatment option given that the patient has to face a long and difficult recovery and rehabilitation period, and the average life span is approximately 20 years.
- Cartilage replacement devices are known in the art. These devices can usually be effected immediately by surgical procedures, resulting in the alleviation of a patient's accompanying pain and also in the rehabilitation of the patient in a relatively short time span.
- the invention relates to an implant and method for resurfacing a large surface area of damaged or destroyed tissue.
- an implant for installation into a site of damaged tissue, said implant comprising; a substitute tissue structure, and an annular anchoring element for anchoring the substitute tissue structure into an annular groove formed in an underlying tissue at or near the implantation site, wherein at least part of the annular anchoring element is bonded to the substitute tissue structure.
- the damaged tissue is cartilage, synovium, tendon, ligament, meniscus, or bone.
- the damaged tissue is cartilage and the annular anchoring element is secured into a groove formed within the subchondral bone.
- the macro- and microstructure of the substitute tissue structure is designed to replicate structurally the tissue which it replaces.
- the surface of the material is contoured to mimic the surface of the natural cartilage such that there is no impingement of the implant against the apposing joint surface.
- the macro- and microstructure of the substitute tissue structure may also be optimized to regenerate and/or repair the desired anatomical features of the tissue that is being regenerated and/or repaired.
- any material used within the substitute tissue structure is biocompatible. Such a material does not elicit an immune response upon implantation.
- At least a part of the substitute tissue structure is formed of a bioresorbable material.
- a bioresorbable material has the ability transiently resorb, preferably in a controllable manner, within the body environment.
- various parts of the substitute tissue structure may be designed to resorb at different rates.
- the rate of resorption is isotropic across the substitute tissue structure.
- tissue substitute structure may be resorbable whilst another region may be non-resorbable.
- the substitute tissue structure can be in the form of a solid non- deformable structure or a substantially deformable structure.
- the substitute tissue structure is substantially porous.
- suitable deformable, porous structures include, but are not limited to, felts, gauzes, gels, and sponges.
- Suitable materials for the substitute tissue structure include, for example; a natural polymer, a synthetic polymer, a ceramic material, a meta,l or combinations thereof.
- polymers can be used.
- synthetic polymer refers to polymers that are not found in nature, even if the polymers are naturally occurring.
- natural polymer refers to polymers that are naturally occurring.
- suitable polymers include, but are not limited to; aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, tyrosine derived carbonates, poly(imniocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups, poly(anhydhdes), polyphosphazenes or blends thereof.
- suitable synthetic polymers for use in the invention include biosynthetic polymers based on sequences found in collagen, elastin, thrombin, fibronectin, starches, poly(amino acid), polypropylene fumarate), gelatine, alginate, pectin, fibrin, silk oxidized cellulose, chitin, chitosan, tropelastin, hyaluronic acid, ribonucleic acids, deoxzyribonucleic acids, polypeptides, proteins, polysaccharides, polynucleotides or combinations thereof.
- suitable examples of natural polymers include, but are not limited to, fibrin-based materials, collagen-based materials, hyaluronic acid-based materials, glycoprotein-based materials, cellulose-based materials, silks, or combinations thereof.
- suitable bioresorbable ceramic particles include, but are not limited to, calcium sulphate, calcium phosphate, calcium carbonate, and hydroxyapatite particles.
- the tissue substitute structure comprises a non-bioresorbable material.
- suitable non-bioresorbable metals include, but not limited to, stainless steel, cobalt chrome, or transition metals such as titanium and zirconium and their respective alloys.
- suitable non-bioresorbable ceramic particles include alumina, and zirconia.
- non-bioresorbable polymers include, but are not limited to, polyethylene, polyvinylacetate, polymethylmethacrylate, polypropylene, poly (ethyl terephthalate), silicone, polyethylene oxide, polyethylene glycol, polyurethanes and polyvinyl alcohol.
- tissue substitute structure may further be associated with an agent that promotes healing and/or regeneration of a tissue.
- Suitable agents include, but are not limited to, anti-inflammatory agents, analgesics, antibiotics, anti-viral agents, growth factors, hormones, cytokines, peptides, proteins, osteogenic agents, chondrogenic agents, anti-resprptive agents, glycosaminoglycans, immunosuppressants, nucleic acids, cells, tissue fragments and/or combinations thereof.
- PRP platelet rich plasma
- PRP platelet rich plasma
- graft stabilization graft stabilization
- wound sealing wound healing and haemostasis.
- PRP concentrates a high number of autologous platelets in a small amount of plasma and mimics the last steps in the coagulation cascade, leading to the formation of a fibrin clot, which consolidates and adheres to the application site in a short period of time.
- Platelet alpha granules contain potent growth factors necessary to begin and substantially accelerate tissue repair and regeneration at the wound site. Growth factors shown to enhance the body's natural healing process include:
- PDGF Platelet Derived Growth Factors initiate connective tissue healing including bone regeneration and repair. PDGF also increases mitogenesis (healing cells), angiogenesis
- TGF- ⁇ Transforming Growth Factor Beta
- EGF Epidermal Growth Factors
- VEGF Vascular Endothelial Growth Factors
- PRP platelet alpha granules, and/ or growth factors derived from PRP are applied to the substitute tissue structure.
- osteogenic proteins also referred to as bone morphogenetic, or morphogenic proteins (BMPs), which are a family of bone-matrix polypeptides which induce formation of new bone by causing the differentiation of mesenchymal ceils to chondroblasts and osteoblasts.
- BMPs bone morphogenetic, or morphogenic proteins
- the substitute tissue structure can also be associated with a cell.
- Suitable cell types include a stem cell, pluripotent cell, chondrocyte progenitor, chondrocyte, osteocyte, fibroblast, osteoclast, osteoblast, chondroblast, endothelial cell, macrophage, adipocyte, monocyte, plasma cell, mast cell, umbilical cord cell, leukocyte, stromal cell, epithelial cell, myoblast, tenocyte, ligament fibroblast or bone marrow cell type, and/or combinations thereof.
- the stem cell is a mesenchymal stem cell.
- the substitute tissue structure is seeded with a cell population.
- This cell population can be of a single cell type or at least two different cell types.
- the cells can be seeded in a manner appropriate to the tissue that they are to form.
- the layers of different cell types can be applied to the substitute tissue structure. Plasma treatment of the substitute tissue structure prior to or after sterilisation can be used to enhance cell adherence.
- the substitute tissue structure can also be associated with at least one tissue fragment.
- the fragment can be derived from, for example, cartilage, meniscus, tendon, ligament, periosteum or bone or bone marrow extract.
- the cell ⁇ s) or tissue fragment(s) used in this invention may be autogenic, allogenic, xenogenic or combinations thereof.
- the annular anchoring element is used to securely anchor the substitute tissue structure into a groove formed within the underlying tissue. This is of particular importance when there are moving parts adjacent to the implantation site which could dislodge the implant.
- the implant is for use in repairing cartilage and the element is anchored into a groove formed in the underlying bone, specifically within the subchondral bone.
- the annular anchoring element is preferably circular or oval, but may be of another shape known to one of skill in the art.
- the annular anchoring element can be a continuous or non- continuous element.
- any material used within the annular anchoring element is biocompatible, that is, it does not elicit an immune response upon implantation.
- at least a part of the annular anchoring element is formed of a bioresorbable material. Such a material has the ability to transiently resorb, preferably in a controllable manner, within the body environment.
- various parts of the annular anchoring element may be designed to resorb at different rates.
- the rate of resorption is isotropic across the annular anchoring element.
- a region of the annular anchoring element may be resorbable while another region may be non-resorbable.
- this element comprises an agent that augments bone growth.
- an agent includes, but is not limited to, an osteogenic stimulant, osteoconductive stimulant and/or an osteoinductive stimulant.
- Osteogenic stimulation of bone formation refers to the stimulation of bone forming or "osteogenic" cells to form new bone growth.
- Osteoconductive stimulation of bone formation refers to the ability of some materials to serve as a scaffold on which bone cells can attach, migrate (meaning move or "crawl”), and grow and divide. In this way, the bone healing response is "conducted" through the graft site.
- Osteoinductive stimulation of bone formation refers to the capacity of many normal chemicals in the body to stimulate primitive "stem cells" or immature bone cells to grow and mature, forming healthy bone tissue.
- Suitable materials for the annular anchoring element include, but not limited to, a natural polymer, a synthetic polymer, a ceramic material, a metal and/or combinations thereof.
- the annular anchoring element includes at least one synthetic polymer selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, tyrosine derived carbonates, poly(imniocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups, poly(anhydrides), polyphosphazenes, and blends thereof.
- synthetic polymer selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, tyrosine derived carbonates, poly(imniocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups, poly(anhydrides), polyphosphazenes, and blends thereof.
- Suitable synthetic polymers for use in the invention can also include biosynthetic polymers based on sequences found in collagen, elastin, thrombin, fibronectin, starches, poly(amino acid), poly(propylene fumarate), gelatine, alginate, pectin, fibrin, silk oxidized cellulose, chitin, chitosan, tropelastin, hyaluronic acid, ribonucleic acids, deoxzyribonucleic acids, polypeptides, proteins, polysaccharides, polynucleotides and combinations thereof.
- suitable examples of natural polymers include, but are not limited to fibrin-based materials, collagen-based materials, hyaluronic acid-based materials, glycoprotein-based materials, cellulose-based materials, silks and combinations thereof.
- the annular anchoring element is molded from polylactide carbonate (PLC), a bioresorbable polymer combined with calcium carbonate. After implantation the PLC gradually resorbs and the calcium carbonate promotes the growth of cancellous, or porous, bone within the bone.
- the annular anchoring element comprises the bioresorbable polymer: poly (D,L-lactide-co-glycolide). After implantation the polymer gradually resorbs.
- the annular anchoring element comprises a bioresorbable ceramic, for example, calcium phosphate, calcium carbonate or hydroxyapatite particles or combinations thereof.
- the annular anchoring element comprises a non-bioresorbable material.
- suitable non-bioresorbable metals include stainless steel, cobalt chrome, or transition metals such as titanium and zirconium and their respective alloys.
- suitable non-bioresorbale ceramic particles include alumina, zirconia and calcium sulphate particles.
- suitable non-bioresorbale polymers include polyethylene, polyvinylacetate, polymethylmethacrylate, polypropylene, poly (ethyl terephthalate), silicone, polyethylene oxide, polyethylene glycol, polyurethanes and polyvinyl alcohol,
- annular anchoring element can be made of a non-porous material, a porous material, or combinations thereof.
- the annular anchoring element may be rigid and therefore preformed to the shape of the groove.
- the element may be deformable, advantageously resiliently deformable, thereby allowing any necessary deformation of the shape of the element to correspond with the shape of the groove.
- the annular anchoring element may be expandable after implantation to fit securely into the groove, for example the annular ring may be formed of a shape memory polymer.
- the osteoconductive properties of the annular anchoring element may be further enhanced by texturing of at least a part of the surface, for example, by etching or grit-blasting.
- the annular anchoring element can be provided with an anti-rotational element, which may, for example, be a threaded ring or a barbed ring.
- Additional elements may be applied to or incorporated within the annular anchoring element to increase its stability within the groove, for example, a tack, a screw, a barb, a pin, or a plug.
- the tissue substitute structure may further be associated with an agent that promotes healing and/or regeneration of a tissue.
- association is herein defined as the agent being incorporated within, attached to, adhered to, applied to, or seeded within, at least a part of the tissue substitute structure.
- Suitable agents include, but are not limited to, anti-inflammatory agents, analgesics, antibiotics, anti-viral agents, growth factors, hormones, cytokines, peptides, proteins, osteogenic agents, chondrogenic agents, anti-resorptive agents, glycosaminoglycans, immunosuppressants, nucleic acids, cells, tissue fragments, and/or combinations thereof.
- At least part of the annular anchoring element is bonded to the undersurface of the tissue substitute structure.
- the undersurface of the tissue substitute structure is defined as that surface which is proximal to the underlying tissue when the implant is implanted at a site.
- the bonding can be by a suitable chemical means and/or physical means.
- the bonding can be achieved by the application of various adhesives.
- the tissue substitute structure is extended radially beyond the annular anchoring element as illustrated in Figures 4 and 5.
- an implant according to the invention for repair of damaged tissue present at or on the surface of a bone in an animal.
- a method for the repair of damaged tissue present in an animal comprising the steps of; i) forming a groove around at least part of the damaged tissue, the groove extending into the underlying tissue below the damaged tissue, ii) removing the tissue about which the groove extends, iii) providing an implant comprising a substitute tissue structure having an annular anchoring element bonded thereto; and iv) inserting the annular anchoring element into the groove.
- the animal is a human or non- human animal.
- the method is used for the repair of damaged cartilage.
- Figure 1 A schematic of an implant according to a first embodiment of the invention.
- Figure 2 A schematic of the implant in Figure 1 seated within subchondral bone.
- Figure 3 A photograph of the implant.
- Figure 4 A schematic of an implant according to a second embodiment of the invention.
- Figure 5 A schematic of the implantation of the implant in Figure 4 into a bone site.
- Felt & ring anchored implants of a resorbable non- woven felt of PLGA (10:90) attached directly to a ring of poly lactide carbonate (PLC) were made according to the method described below:
- Non-woven (un-bonded) poly(L-lactic-co-glycolic) acid (PLGA 10:90) scaffolds were produced with the following specification:
- Powdered polycaprolactone, PCL (CAPA 686, Solway) is dissolved in Chloroform (GPC Grade) to form a 6% w/v solution.
- the PCL solution is then introduced onto at least part of one side of the PLC ring using a small spatula.
- the PLGA non-woven felt is then applied to the side of the PLC ring provided with the PCL solution to bond them together.
- the felt & ring implants are then placed on a release paper and air-dried in a fume cupboard overnight and subsequently dried in a vacuum oven at 40°C for 24 hours.
- FIG 1 shows an implant 1 of a first embodiment.
- the implant 1 includes a substantially circular scaffold, or substitute tissue structure 2, and an annular anchoring element 3, each having the same diameter.
- the scaffold 2 includes a first end 2a and a second end 2b.
- the annular anchoring element 3 includes a first end 3a having an opening 3b and a second end 3c having an opening 3d.
- Figure 2 shows a cross-sectional view of the implant 1 anchored into subchondral bone 5.
- the annular anchoring element 3 is retained within an annular groove 6 formed within the subchondral bone 5 and which surrounds a cartilage defect 8.
- the implant 1 is anchored into subchondral bone 5 by first forming the groove 6 around at least part of damaged cartilage and/or bone tissue (not shown).
- the groove 6 is formed by a reaming device or other instrument known to one of ordinary skill in the art.
- the damaged tissue is then removed, via a scraping device, wire brush, or other instrument known to one of ordinary skill in the art, and the implant 1 is inserted into the groove 6.
- the scaffold 2 is of an appropriate thickness such that when the anchoring element 3 is seated in the subchondral bone 5, the first end 2a of the scaffold 2 lies flush with the surrounding cartilage 7.
- Figures 3A and 3B show a plan view and a cross-sectional view, respectively, of the implant 1.
- FIG 4 shows an implant 11 according to a second embodiment of the present disclosure.
- This implant 11 is designed for implantation into a site of a cartilage defect, as will be further described below.
- the annular anchoring element 13 is retained within an annular groove 14 formed within the subchondral bone 15 and which surrounds a cartilage defect 18, as will be further described in Figure 5.
- the substitute tissue structure 12 is of an appropriate thickness such that when the anchoring element is seated in the subchondral bone 15, the first end 12a of the structure 12, lies flush with the surrounding cartilage 17.
- the substitute tissue structure 12 has a larger diameter than the annular anchoring element 13, such that the periphery 19 of the substitute tissue structure 12 extends radially of the annular anchoring element 13.
- the upper surface of the subchondral bone 15 forms a ledge 20 onto which this radially extended region 19 is supported.
- An advantage of this region 19 is that the scaffold, or substitute tissue structure 12, is restricted from being pulled down into the groove 14.
- Figures 5A-5F show the implantation of the implant 11.
- Figure 5A shows the cartilage defect 18.
- Figure 5B shows the preparation of an annular groove 30 using a saw trephine 40 and a guide 50.
- Figure 5C shows the defect site 70 after preparation of the annular groove 30.
- Figure 5D shows preparation of the ledge 20 of subchondral bone 15, as described above, using a cutter 60.
- Figure 5E shows the defect site 70 after preparation of the ledge 20.
- Figure 5F shows the implant 11 implanted into the prepared defect site 70.
- Other tools known to one of ordinary skill in the art may be used to prepare the annular groove 30 and the ledge 20.
- the implants 1 ,11 of the present disclosure are used, as described above, in the repair of tissue, such as cartilage tissue, in human or non-human animals. Formation of the grooves and removal of the damaged tissue induces bleeding of the subchondral bone and stimulates formation of a blood clot within/around the scaffold.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008321357A AU2008321357A1 (en) | 2007-11-16 | 2008-02-07 | Annular ring implant |
EP08729277A EP2224883A1 (fr) | 2007-11-16 | 2008-02-07 | Implant annulaire |
JP2010534065A JP2011502703A (ja) | 2007-11-16 | 2008-02-07 | 環状リング移植片 |
PCT/US2008/053300 WO2009064509A1 (fr) | 2007-11-16 | 2008-02-07 | Implant annulaire |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USPCT/US2007/084905 | 2007-11-16 | ||
PCT/US2007/084905 WO2008061216A2 (fr) | 2006-11-18 | 2007-11-16 | Implant de bague annulaire |
PCT/US2008/053300 WO2009064509A1 (fr) | 2007-11-16 | 2008-02-07 | Implant annulaire |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009064509A1 true WO2009064509A1 (fr) | 2009-05-22 |
Family
ID=39596803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/053300 WO2009064509A1 (fr) | 2007-11-16 | 2008-02-07 | Implant annulaire |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009064509A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030036801A1 (en) * | 2001-07-16 | 2003-02-20 | Schwartz Herbert E. | Cartilage repair apparatus and method |
WO2003028535A2 (fr) * | 2001-10-01 | 2003-04-10 | Scandius Biomedical, Inc. | Appareil et procede permettant la reparation de lesions ou de la perte du cartilage articulaire |
US20030220700A1 (en) * | 2002-05-22 | 2003-11-27 | Hammer Joseph J. | Attachment of absorbable tissue scaffolds ot fixation devices |
WO2005051242A1 (fr) * | 2003-10-28 | 2005-06-09 | Xiros Plc | Reparation de tissu altere sur un site osseux |
-
2008
- 2008-02-07 WO PCT/US2008/053300 patent/WO2009064509A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030036801A1 (en) * | 2001-07-16 | 2003-02-20 | Schwartz Herbert E. | Cartilage repair apparatus and method |
WO2003028535A2 (fr) * | 2001-10-01 | 2003-04-10 | Scandius Biomedical, Inc. | Appareil et procede permettant la reparation de lesions ou de la perte du cartilage articulaire |
US20030220700A1 (en) * | 2002-05-22 | 2003-11-27 | Hammer Joseph J. | Attachment of absorbable tissue scaffolds ot fixation devices |
WO2005051242A1 (fr) * | 2003-10-28 | 2005-06-09 | Xiros Plc | Reparation de tissu altere sur un site osseux |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080119947A1 (en) | Annular Ring Implant | |
US7427293B2 (en) | Osteochondral plug graft, kit and method | |
US8795361B2 (en) | Osteochondral plug graft, kit and method | |
JP4635276B2 (ja) | 生体組織における欠損を治療するための装置および方法 | |
US7837740B2 (en) | Two piece cancellous construct for cartilage repair | |
US8435551B2 (en) | Cancellous construct with support ring for repair of osteochondral defects | |
US20060293760A1 (en) | Soft tissue implants with improved interfaces | |
US20190175786A1 (en) | Electrospun fibers for the repair and regrowth of hyaline cartilage | |
EP3197496B1 (fr) | Réparation du cartilage articulaire | |
US9981061B2 (en) | Devices and methods for treating defects in the tissue of a living being | |
EP2224883A1 (fr) | Implant annulaire | |
WO2009064509A1 (fr) | Implant annulaire |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08729277 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008321357 Country of ref document: AU Ref document number: 2010534065 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008321357 Country of ref document: AU Date of ref document: 20080207 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008729277 Country of ref document: EP |